Draft:Dr. Paul J. Kenny: Difference between revisions

This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the “Edit” tab at the top of the window. To be accepted, a draft should: It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Italian-Irish neurologist

Paul J. Kenny is the Ward-Coleman Professor and Chair of the Nash Family Department of Neuroscience^[1] and Interim Director of the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City.^[1] Dr. Kenny also serves as the Director of the Drug Discovery Institute^[1] and Director of the NIDA T32 Training Program in Substance Use Disorders at ISMMS.^[1]

Internationally recognized for his research on the neurobiology of addiction, psychiatric disorders, and obesity, Dr. Kenny has published over 150 peer-reviewed papers and has an h-index of 71 with over 20,000 citations.^[2]

Biography

Education

Dr. Kenny earned a Bachelor of Arts in Biochemistry from Trinity College Dublin in 1996, followed by a Ph.D. in Neuropsychopharmacology from King’s College London in 2000. He subsequently moved to the United States for postdoctoral research in neuropharmacology at The Scripps Research Institute, La Jolla, California (2000–2005).^[3]

Career

After completing his postdoctoral fellowship, Kenny joined The Scripps Research Institute as a staff scientist (2005–2006), later rising to Assistant Professor (2006), Associate Professor (2008), and Associate Professor with tenure (2011) in the Department of Molecular Therapeutics. In 2014, Kenny joined the Icahn School of Medicine at Mount Sinai, serving as Professor and Chair of the Department of Pharmacology and Systems Therapeutics before becoming Chair of the Nash Family Department of Neuroscience in 2016.^[4] He currently holds the Ward-Coleman Professorship and directs both the Drug Discovery Institute and the NIDA-funded T32 Training Program in Substance Use Disorders. In 2025, Kenny was appointed Interim Director of the Friedman Brain Institute. Kenny is also a co-founder of Eolas Therapeutics, Inc.^[5], a biotechnology company developing novel therapeutics for substance use disorders.

References